Boston Scientific (BSX)
(Delayed Data from NYSE)
$74.03 USD
-1.56 (-2.06%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $74.02 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum C VGM
Price, Consensus and EPS Surprise
BSX 74.03 -1.56(-2.06%)
Will BSX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BSX
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised
Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up
3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now
Other News for BSX
Boston Scientific Elects David Habiger to Board of Directors
DexCom added to Raymond James analyst current favorite list
Boston Scientific removed from 'Analyst Current Favorites' at Raymond James
Boston Scientific Appoints New Director and Expands Board
Fidelity Puritan Fund Q2 2024 Review